Related Experiment Video
Updated: Jul 6, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Critical aspects of the Bayesian approach to phase I cancer trials
Beat Neuenschwander1, Michael Branson, Thomas Gsponer
1Novartis Pharma AG, Lichstrasse 35, 4056 Basel, Switzerland. beat.neuenschwander@novartis.com
Abstract:
The Bayesian approach to finding the maximum-tolerated dose in phase I cancer trials is discussed. The suggested approach relies on a realistic dose-toxicity model, allows one to include prior information, and supports clinical decision making by presenting within-trial information in a transparent way. The modeling and decision-making components are flexible enough to be extendable to more complex settings. Critical aspects are emphasized and a comparison with the continual reassessment method (CRM) is performed with data from an actual trial and a simulation study. The comparison revealed similar operating characteristics while avoiding some of the difficulties encountered in the actual trial when applying the CRM.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Kaplan-Meier Approach
Cancer Survival Analysis
Preclinical Development: Overview